IL187508A0 - Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment - Google Patents
Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatmentInfo
- Publication number
- IL187508A0 IL187508A0 IL187508A IL18750807A IL187508A0 IL 187508 A0 IL187508 A0 IL 187508A0 IL 187508 A IL187508 A IL 187508A IL 18750807 A IL18750807 A IL 18750807A IL 187508 A0 IL187508 A0 IL 187508A0
- Authority
- IL
- Israel
- Prior art keywords
- rapamycins
- combination therapy
- cancer treatment
- urea compound
- mtor inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05011477 | 2005-05-27 | ||
PCT/EP2006/004524 WO2006125540A1 (en) | 2005-05-27 | 2006-05-13 | Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
IL187508A0 true IL187508A0 (en) | 2008-06-05 |
Family
ID=36636325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL187508A IL187508A0 (en) | 2005-05-27 | 2007-11-20 | Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1888067A1 (ru) |
JP (1) | JP2008542214A (ru) |
KR (1) | KR20080018908A (ru) |
CN (1) | CN101257903A (ru) |
AU (1) | AU2006251429A1 (ru) |
BR (1) | BRPI0610048A2 (ru) |
CA (1) | CA2609389A1 (ru) |
IL (1) | IL187508A0 (ru) |
MX (1) | MX2007014726A (ru) |
RU (1) | RU2007148266A (ru) |
WO (1) | WO2006125540A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
ME00294B (me) | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2009519265A (ja) * | 2005-12-15 | 2009-05-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ウイルス感染を処置するためのジアリールウレア |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008089388A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
EP2129376B1 (en) | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
JP2011525503A (ja) * | 2008-06-25 | 2011-09-22 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全を処置するためのジアリールウレア |
ES2614130T3 (es) * | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
AU2010253820A1 (en) * | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
CN102775385A (zh) * | 2011-05-10 | 2012-11-14 | 湖南有色凯铂生物药业有限公司 | N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用 |
CN102643229A (zh) * | 2012-01-17 | 2012-08-22 | 湖南有色凯铂生物药业有限公司 | N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用 |
CN102885814A (zh) * | 2012-01-17 | 2013-01-23 | 湖南有色凯铂生物药业有限公司 | 一种化合物及其作为抗癌药物的应用 |
CN102940884B (zh) * | 2012-11-19 | 2013-11-06 | 上海市肿瘤研究所 | 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用 |
WO2014145386A2 (en) | 2013-03-15 | 2014-09-18 | University Of Florida Research Foundation Incorporated | Novel allosteric inhibitors of thymidylate synthase |
AU2015365497B2 (en) * | 2014-12-17 | 2020-07-02 | Pfizer Inc. | Formulations of a PI3k/mTOR-inhibitor for intravenous administration |
CN104892632B (zh) * | 2015-06-03 | 2017-12-26 | 道中道(菏泽)制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
CN104906086A (zh) * | 2015-06-24 | 2015-09-16 | 安徽四正医药科技有限公司 | 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用 |
WO2016209688A1 (en) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of cancer and uses thereof |
KR102544163B1 (ko) * | 2022-08-10 | 2023-06-16 | 주식회사 하이밸 | 소음저감형 유량 및 압력 조절용 감압밸브 |
CN115804844B (zh) * | 2022-09-26 | 2024-05-10 | 郑州大学 | 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00294B (me) * | 2003-07-23 | 2011-05-10 | Bayer Pharmaceuticals Corp | Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti |
-
2006
- 2006-05-13 CA CA002609389A patent/CA2609389A1/en not_active Abandoned
- 2006-05-13 EP EP06724813A patent/EP1888067A1/en not_active Withdrawn
- 2006-05-13 RU RU2007148266/15A patent/RU2007148266A/ru not_active Application Discontinuation
- 2006-05-13 JP JP2008512730A patent/JP2008542214A/ja active Pending
- 2006-05-13 AU AU2006251429A patent/AU2006251429A1/en not_active Abandoned
- 2006-05-13 CN CNA2006800185177A patent/CN101257903A/zh active Pending
- 2006-05-13 KR KR1020077030272A patent/KR20080018908A/ko not_active Application Discontinuation
- 2006-05-13 BR BRPI0610048-1A patent/BRPI0610048A2/pt not_active Application Discontinuation
- 2006-05-13 WO PCT/EP2006/004524 patent/WO2006125540A1/en active Application Filing
- 2006-05-13 MX MX2007014726A patent/MX2007014726A/es not_active Application Discontinuation
-
2007
- 2007-11-20 IL IL187508A patent/IL187508A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006251429A1 (en) | 2006-11-30 |
WO2006125540A1 (en) | 2006-11-30 |
JP2008542214A (ja) | 2008-11-27 |
BRPI0610048A2 (pt) | 2010-05-25 |
CA2609389A1 (en) | 2006-11-30 |
CN101257903A (zh) | 2008-09-03 |
MX2007014726A (es) | 2008-02-14 |
KR20080018908A (ko) | 2008-02-28 |
RU2007148266A (ru) | 2009-07-10 |
EP1888067A1 (en) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL187508A0 (en) | Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment | |
IL187085A0 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
EP1814854A4 (en) | Cationic cereals and analogues thereof, and their use for the prevention or treatment of cancer | |
EP1487436A4 (en) | POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | |
EP2024018A4 (en) | PORTABLE ARRANGEMENTS, SYSTEMS AND METHOD FOR PROVIDING FUNCTIONAL OR THERAPEUTIC NEUROSTIMULATION | |
IL188588A0 (en) | Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
ZA200904518B (en) | Zone coated filter, emission treatment systems and methods | |
HK1098072A1 (en) | Medicaments and methods for treating headache | |
IL191938A (en) | The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment | |
HK1250018B (zh) | 用於治療胰腺癌的雷帕黴素衍生物 | |
ZA200709620B (en) | Methods for treating drug resistant cancer | |
HK1103354A1 (en) | Combination therapy for preventing or treating alzheimers disease, and kit therefor | |
EP1535971A4 (en) | TREATED PIGMENT, ITS USE, AND COMPOUND FOR THE TREATMENT OF PIGMENTS | |
IL178261A0 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
IL180256A0 (en) | Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer | |
EP1680073A4 (en) | COMPOUNDS AND METHOD OF TREATING CANCER | |
EP1830847A4 (en) | CANCER TREATMENT | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
BRPI0618198A2 (pt) | métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia | |
WO2006060819A3 (en) | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells | |
EP2574340A3 (en) | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor | |
EP1836165A4 (en) | DIPYRROLE COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER OR VIRAL DISEASES | |
WO2007010013A3 (en) | Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases | |
IL226362A0 (en) | compounds, and methods for treating cancer | |
AU2003258176A8 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |